HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
32:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
the patient with resistant hypertension:  :@0.076190:0.099847:0.719858:0.099847:0.719858:0.063183:0.076190:0.063183:0.014111:0.020159:0.021503:0.009407:0.022175:0.022175:0.010079:0.008063:0.021503:0.020159:0.010079:0.009407:0.026878:0.008063:0.010079:0.020159:0.009407:0.010751:0.021503:0.014783:0.008063:0.014783:0.010079:0.022175:0.020159:0.010079:0.009407:0.020159:0.019487:0.022175:0.021503:0.010751:0.010079:0.021503:0.020159:0.014783:0.008063:0.021503:0.020159:0.009407:0.009340:0.009407
a practical approach:@0.076190:0.128069:0.426280:0.128069:0.426280:0.091406:0.076190:0.091406:0.022175:0.009407:0.022175:0.010751:0.022175:0.021503:0.010079:0.008063:0.021503:0.022175:0.008063:0.009407:0.022175:0.022175:0.022175:0.010751:0.021503:0.022175:0.021503:0.020159
b rayner:@0.076190:0.169924:0.147418:0.169924:0.147418:0.151592:0.076190:0.151592:0.009743:0.004704:0.009743:0.011087:0.009743:0.010079:0.010751:0.005376
MBChB, FCp, MMed, phD:@0.076190:0.182623:0.239624:0.182623:0.239624:0.168594:0.076190:0.168594:0.012351:0.007714:0.010926:0.008198:0.007714:0.003723:0.003723:0.006518:0.010926:0.007956:0.003723:0.003723:0.012351:0.012351:0.008735:0.009206:0.003723:0.003723:0.007956:0.008198:0.009999
Emeritus Professor, Division of Nephrology and Hypertension,:@0.076190:0.201239:0.464904:0.201239:0.464904:0.187210:0.076190:0.187210:0.007203:0.012606:0.008735:0.004045:0.002688:0.004556:0.008171:0.005214:0.003723:0.007956:0.004045:0.008803:0.004220:0.008735:0.005214:0.005214:0.008803:0.004045:0.003723:0.003723:0.009999:0.002688:0.007445:0.002688:0.005214:0.002688:0.008803:0.008198:0.003723:0.008803:0.004220:0.003723:0.009945:0.008735:0.009165:0.008198:0.004045:0.008803:0.002688:0.008803:0.009045:0.007203:0.003723:0.009179:0.008198:0.009206:0.003723:0.009179:0.007203:0.009165:0.008735:0.004045:0.004556:0.008735:0.008198:0.005214:0.002688:0.008803:0.008198:0.003723
Department of Medicine, University of Cape Town, Cape Town:@0.076190:0.214724:0.480951:0.214724:0.480951:0.200695:0.076190:0.200695:0.009999:0.008735:0.009165:0.009179:0.004045:0.004556:0.012606:0.008735:0.008198:0.004556:0.003346:0.008803:0.004220:0.003346:0.012351:0.008735:0.009206:0.002688:0.008695:0.002688:0.008198:0.008735:0.003723:0.003360:0.008803:0.008198:0.002688:0.007445:0.008735:0.004045:0.005214:0.002688:0.004556:0.007203:0.003360:0.008803:0.004220:0.003346:0.010926:0.009179:0.009165:0.008735:0.003360:0.005725:0.008803:0.011168:0.008198:0.003723:0.003346:0.010926:0.009179:0.009165:0.008735:0.003360:0.005725:0.008803:0.011168:0.008198
Hypertension is the world’s leading risk factor for cardio-:@0.076190:0.245286:0.480942:0.245286:0.480942:0.229503:0.076190:0.229503:0.010326:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.003901:0.003024:0.005866:0.003916:0.005125:0.009223:0.009827:0.003901:0.012564:0.009903:0.004551:0.003024:0.010357:0.005307:0.005866:0.003901:0.003024:0.009827:0.010326:0.010357:0.003024:0.009223:0.010175:0.003901:0.004551:0.003024:0.005866:0.007590:0.003901:0.004747:0.010326:0.009782:0.005125:0.009903:0.004551:0.003901:0.004747:0.009903:0.004551:0.003901:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.005020
vascular disease (CVD), stroke,  disability,  and death. :@0.076190:0.260053:0.485145:0.260053:0.485145:0.244270:0.076190:0.244270:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.007726:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.007726:0.005579:0.012292:0.010614:0.011249:0.005579:0.004188:0.007726:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.004188:0.003523:0.010357:0.003024:0.005866:0.010326:0.010311:0.003024:0.003024:0.003024:0.005125:0.008104:0.004188:0.004188:0.003553:0.010326:0.009223:0.010357:0.007726:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188:0.004188
Despite a steady improvement in control rates over the :@0.076190:0.274819:0.485160:0.274819:0.485160:0.259037:0.076190:0.259037:0.011249:0.009827:0.005866:0.010311:0.003024:0.005125:0.009827:0.004354:0.010326:0.004354:0.005866:0.005125:0.009827:0.010326:0.010357:0.008104:0.004354:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.014182:0.009827:0.009223:0.005125:0.004354:0.003024:0.009223:0.004354:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.004339:0.004551:0.010326:0.005125:0.009827:0.005866:0.004354:0.009903:0.008376:0.009827:0.004551:0.004339:0.005125:0.009223:0.009827:0.004188
past 30 years, a significant percentage of patients are :@0.076190:0.289586:0.485145:0.289586:0.485145:0.273803:0.076190:0.273803:0.010311:0.010326:0.005866:0.005125:0.005367:0.008376:0.008376:0.005367:0.008104:0.009827:0.010326:0.004551:0.005866:0.004188:0.005367:0.010326:0.005367:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.005367:0.010311:0.009827:0.004551:0.009782:0.009827:0.009223:0.005125:0.010326:0.010175:0.009827:0.005352:0.009903:0.004747:0.005352:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005367:0.010326:0.004551:0.009827:0.004188
treatment-resistant and fail to meet blood-pressure (Bp) :@0.076190:0.304353:0.485115:0.304353:0.485115:0.288570:0.076190:0.288570:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.005020:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.005125:0.004188:0.010326:0.009223:0.010357:0.004203:0.004747:0.010326:0.003024:0.003024:0.004203:0.005125:0.009903:0.004188:0.014182:0.009827:0.009827:0.005125:0.004188:0.010311:0.003024:0.009903:0.009903:0.010357:0.005020:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.004188:0.005579:0.008678:0.008950:0.005579:0.004188
targets despite appropriate treatment. Resistant hyper-:@0.076190:0.319119:0.480957:0.319119:0.480957:0.303337:0.076190:0.303337:0.005125:0.010326:0.004551:0.010175:0.009827:0.005125:0.005866:0.004551:0.010357:0.009827:0.005866:0.010311:0.003024:0.005125:0.009827:0.004566:0.010326:0.010311:0.010311:0.004551:0.009903:0.010311:0.004551:0.003024:0.010326:0.005125:0.009827:0.004551:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.004551:0.009177:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.005125:0.004551:0.009223:0.008104:0.010311:0.009827:0.004551:0.005020
tension  (RH) is common,  with the  prevalence ranging :@0.076190:0.333886:0.485145:0.333886:0.485145:0.318103:0.076190:0.318103:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004188:0.002343:0.005579:0.009177:0.010326:0.005579:0.006547:0.003024:0.005866:0.006547:0.009782:0.009903:0.014182:0.014182:0.009903:0.009223:0.004188:0.004188:0.002343:0.012564:0.003024:0.005125:0.009223:0.006547:0.005125:0.009223:0.009827:0.004188:0.002343:0.010311:0.004551:0.009827:0.008376:0.010326:0.003024:0.009827:0.009223:0.009782:0.009827:0.006547:0.004551:0.010326:0.009223:0.010175:0.003024:0.009223:0.010175:0.004188
from 12-15%  of population-based studies  to 15-18%  in :@0.076190:0.348653:0.485145:0.348653:0.485145:0.332870:0.076190:0.332870:0.004747:0.004551:0.009903:0.014182:0.006804:0.008376:0.008376:0.005020:0.008376:0.008376:0.011717:0.004188:0.002631:0.009903:0.004747:0.006804:0.010311:0.009903:0.010311:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.006804:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.004188:0.002631:0.005125:0.009903:0.006804:0.008376:0.008376:0.005020:0.008376:0.008376:0.011717:0.004188:0.002631:0.003024:0.009223:0.004188
clinic-based reports.  The prognosis for RH is adverse as :@0.076190:0.363419:0.485130:0.363445:0.485130:0.347663:0.076190:0.347637:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.003946:0.004551:0.009827:0.010311:0.009903:0.004551:0.005125:0.005866:0.004188:0.012140:0.003931:0.006441:0.009223:0.009827:0.003931:0.010311:0.004551:0.009903:0.010175:0.009223:0.009903:0.005866:0.003024:0.005866:0.003931:0.004747:0.009903:0.004551:0.003931:0.009177:0.010326:0.003931:0.003024:0.005866:0.003946:0.010326:0.010357:0.008376:0.009827:0.004551:0.005866:0.009827:0.003946:0.010326:0.005866:0.373310
1,2:@0.224017:0.358146:0.236162:0.358146:0.236162:0.348993:0.224017:0.348993:0.004858:0.002429:0.004858
these individuals remain at increased risk for target or-:@0.076190:0.378212:0.480942:0.378212:0.480942:0.362429:0.076190:0.362429:0.005125:0.009223:0.009827:0.005866:0.009827:0.005609:0.003024:0.009223:0.010357:0.003024:0.008376:0.003024:0.010357:0.009192:0.010326:0.003024:0.005866:0.005624:0.004551:0.009827:0.014182:0.010326:0.003024:0.009223:0.005609:0.010326:0.005125:0.005609:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.005609:0.004551:0.003024:0.005866:0.007590:0.005609:0.004747:0.009903:0.004551:0.005609:0.005125:0.010326:0.004551:0.010175:0.009827:0.005125:0.005609:0.009903:0.004551:0.005020
gan damage, morbidity, and mortality. For example, in :@0.076190:0.392978:0.485160:0.392978:0.485160:0.377196:0.076190:0.377196:0.010175:0.010326:0.009223:0.004642:0.010357:0.010326:0.014182:0.010326:0.010175:0.009827:0.004188:0.004642:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.008104:0.004188:0.004642:0.010326:0.009223:0.010357:0.004642:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188:0.004642:0.007333:0.009903:0.004551:0.004626:0.009827:0.007257:0.010326:0.014182:0.010311:0.003024:0.009827:0.004188:0.004642:0.003024:0.009223:0.004188
a large retrospective study of more than 200 000 patients :@0.076190:0.407745:0.485130:0.407745:0.485130:0.391962:0.076190:0.391962:0.010326:0.002857:0.003024:0.010326:0.004551:0.010175:0.009827:0.002857:0.004551:0.009827:0.005125:0.004551:0.009903:0.005866:0.010311:0.009812:0.009782:0.005125:0.003024:0.008376:0.009827:0.002857:0.005866:0.005125:0.009192:0.010357:0.008104:0.002857:0.009903:0.004747:0.002857:0.014182:0.009903:0.004551:0.009827:0.002842:0.005125:0.009223:0.010326:0.009223:0.002857:0.008376:0.008376:0.008376:0.002857:0.008376:0.008376:0.008376:0.002857:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188
with incident hypertension, those with resistant hyper-:@0.076190:0.422512:0.480957:0.422512:0.480957:0.406729:0.076190:0.406729:0.012564:0.003024:0.005125:0.009223:0.006834:0.003024:0.009223:0.009782:0.003024:0.010357:0.009827:0.009223:0.005125:0.006834:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004188:0.006834:0.005125:0.009223:0.009903:0.005866:0.009827:0.006834:0.012564:0.003024:0.005125:0.009223:0.006834:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.005125:0.006834:0.009223:0.008104:0.010311:0.009827:0.004551:0.005020
tension  were  47% more  likely to  suffer  the  combined :@0.076190:0.437278:0.485145:0.437278:0.485145:0.421496:0.076190:0.421496:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004188:0.003251:0.012564:0.009827:0.004551:0.009827:0.004188:0.003251:0.008376:0.008376:0.011717:0.007454:0.014182:0.009903:0.004551:0.009827:0.004188:0.003251:0.003024:0.003024:0.007590:0.009827:0.003024:0.008104:0.007454:0.005125:0.009903:0.004188:0.003251:0.005866:0.009192:0.004747:0.004747:0.009827:0.004551:0.004188:0.003251:0.005125:0.009223:0.009827:0.004188:0.003251:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.009827:0.010357:0.004188
outcomes of death, myocardial infarction, heart failure, :@0.076190:0.452045:0.485145:0.452045:0.485145:0.436262:0.076190:0.436262:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.005866:0.003765:0.009903:0.004747:0.003780:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188:0.003780:0.014182:0.008104:0.009903:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.003024:0.003780:0.003024:0.009223:0.004747:0.010326:0.004551:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.003780:0.009223:0.009827:0.010326:0.004551:0.005125:0.003780:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.004188
stroke, or chronic kidney disease (CKD).  It is therefore :@0.076190:0.466812:0.485171:0.466834:0.485171:0.451052:0.076190:0.451029:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.005851:0.009903:0.004551:0.005851:0.009782:0.009223:0.004551:0.009903:0.009223:0.003024:0.009782:0.005851:0.007590:0.003024:0.010357:0.009223:0.009827:0.008104:0.005866:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.005866:0.005579:0.012292:0.008935:0.011249:0.005579:0.004188:0.004864:0.005866:0.003417:0.005125:0.005866:0.003024:0.005866:0.005866:0.005125:0.009223:0.009827:0.004551:0.009827:0.004747:0.009903:0.004551:0.009827:0.237878
3:@0.373510:0.461536:0.378368:0.461536:0.378368:0.452382:0.373510:0.452382:0.004858
critical that general practitioners and specialists have a :@0.076186:0.481601:0.485125:0.481601:0.485125:0.465818:0.076186:0.465818:0.009782:0.004551:0.003024:0.005125:0.003024:0.009782:0.010326:0.003024:0.004097:0.005125:0.009223:0.010326:0.005125:0.004097:0.010175:0.009827:0.009223:0.009827:0.004551:0.010326:0.003024:0.004097:0.010311:0.004551:0.010326:0.009782:0.005125:0.003024:0.005125:0.003024:0.009903:0.009223:0.009827:0.004551:0.005866:0.004097:0.010326:0.009223:0.010357:0.004097:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.005866:0.005125:0.005866:0.004112:0.009223:0.010326:0.008376:0.009827:0.004097:0.010326:0.004188
sound clinical approach to this important problem.:@0.076186:0.496368:0.448129:0.496368:0.448129:0.480585:0.076186:0.480585:0.005866:0.009903:0.009192:0.009223:0.010357:0.004188:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.004188:0.010326:0.010311:0.010311:0.004551:0.009903:0.010326:0.009782:0.009223:0.004188:0.005125:0.009903:0.004188:0.005125:0.009223:0.003024:0.005866:0.004188:0.003024:0.014182:0.010311:0.009903:0.004551:0.005125:0.010326:0.009223:0.005125:0.004188:0.010311:0.004551:0.009903:0.010311:0.003024:0.009827:0.014182:0.004188
DefinitiOn:@0.076190:0.529891:0.173759:0.529891:0.173759:0.509727:0.076190:0.509727:0.012935:0.009609:0.008870:0.005174:0.013674:0.005174:0.007761:0.005174:0.015522:0.013674
Resistant hypertension is defined as the blood pressure :@0.076190:0.546439:0.485145:0.546439:0.485145:0.530657:0.076190:0.530657:0.009177:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.005125:0.005337:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.005322:0.003024:0.005866:0.005337:0.010357:0.009827:0.003681:0.003681:0.009223:0.009827:0.010357:0.005322:0.010326:0.005866:0.005337:0.005125:0.009223:0.009827:0.005322:0.010311:0.003024:0.009903:0.009903:0.010357:0.005322:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.004188
of a hypertensive patient that remains elevated above :@0.076190:0.561206:0.485160:0.561206:0.485160:0.545423:0.076190:0.545423:0.009903:0.004747:0.004475:0.010326:0.004475:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.004475:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.004475:0.005125:0.009223:0.010326:0.005125:0.004475:0.004551:0.009827:0.014182:0.010326:0.003024:0.009223:0.005866:0.004475:0.009827:0.003024:0.009827:0.008376:0.010326:0.005125:0.009827:0.010357:0.004475:0.010326:0.010311:0.009903:0.008376:0.009827:0.004188
goal (>140/90  in  south  Africa) despite the concurrent :@0.076190:0.575973:0.485160:0.575973:0.485160:0.560190:0.076190:0.560190:0.010175:0.009903:0.010326:0.003024:0.006577:0.005579:0.009162:0.008376:0.008376:0.008376:0.006607:0.008376:0.008376:0.004188:0.002404:0.003024:0.009223:0.004188:0.002389:0.007529:0.009903:0.009192:0.005125:0.009223:0.004188:0.002374:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.005579:0.006577:0.010357:0.009827:0.005866:0.010311:0.003024:0.005125:0.009827:0.006577:0.005125:0.009223:0.009827:0.006577:0.009782:0.009903:0.009223:0.009782:0.009192:0.004551:0.004551:0.009827:0.009223:0.005125:0.004188
use  of  ≥3  antihypertensive  agents  of  different  classes, :@0.076190:0.590739:0.485130:0.590739:0.485130:0.574957:0.076190:0.574957:0.009192:0.005866:0.009827:0.004188:0.002419:0.009903:0.004747:0.004188:0.002404:0.008300:0.008376:0.004188:0.002419:0.010326:0.009223:0.005125:0.003024:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.004188:0.002419:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.004188:0.002404:0.009903:0.004747:0.004188:0.002404:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.005125:0.004188:0.002404:0.009782:0.003024:0.010326:0.005866:0.005866:0.009827:0.005866:0.004188:0.004188
that include a long-acting  calcium-channel blocker :@0.076190:0.605506:0.485145:0.605506:0.485145:0.589723:0.076190:0.589723:0.005125:0.009223:0.010326:0.005125:0.009056:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.009056:0.010326:0.009056:0.003024:0.009903:0.009223:0.010175:0.005020:0.010326:0.009782:0.005125:0.003024:0.009223:0.010175:0.004188:0.004853:0.009782:0.010326:0.003024:0.009782:0.003024:0.009192:0.014182:0.005020:0.009782:0.009223:0.010326:0.009223:0.009223:0.009827:0.003024:0.009056:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.004188
(CCB), an angiotensin-converting enzyme (ACE) inhibi-:@0.076190:0.620272:0.480942:0.620272:0.480942:0.604490:0.076190:0.604490:0.005579:0.012292:0.012292:0.008678:0.005579:0.004188:0.004853:0.010326:0.009223:0.004853:0.010326:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.005020:0.009782:0.009903:0.009223:0.008376:0.009827:0.004536:0.005125:0.003024:0.009223:0.010175:0.004853:0.009827:0.009223:0.006426:0.008104:0.014182:0.009827:0.004853:0.005579:0.011188:0.012292:0.008104:0.005579:0.004853:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005020
tor or angiotensin receptor blocker (ARB), and a diuretic :@0.076190:0.635039:0.485145:0.635039:0.485145:0.619256:0.076190:0.619256:0.005125:0.009903:0.004551:0.003417:0.009903:0.004551:0.003432:0.010326:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.003432:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.003417:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.003432:0.005579:0.011188:0.009177:0.008678:0.005579:0.004188:0.003432:0.010326:0.009223:0.010357:0.003432:0.010326:0.003432:0.010357:0.003024:0.009192:0.004551:0.009827:0.005125:0.003024:0.009782:0.004188
(thiazide or thiazide-like).  All agents should be adminis-:@0.076190:0.649806:0.480953:0.649828:0.480953:0.634046:0.076190:0.634023:0.005579:0.005125:0.009223:0.003024:0.010326:0.006426:0.003024:0.010357:0.009827:0.004354:0.009903:0.004551:0.004339:0.005125:0.009223:0.003024:0.010326:0.006426:0.003024:0.010357:0.009827:0.005020:0.003024:0.003024:0.007590:0.009827:0.005579:0.004188:0.004864:0.004354:0.011188:0.003024:0.003024:0.004354:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.004339:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004354:0.010311:0.009827:0.004354:0.010326:0.010357:0.014182:0.003024:0.009223:0.003024:0.005866:0.003292
4:@0.257835:0.644530:0.262693:0.644530:0.262693:0.635376:0.257835:0.635376:0.004858
tered at maximum or maximally tolerated doses and at :@0.076187:0.664595:0.485126:0.664595:0.485126:0.648812:0.076187:0.648812:0.005125:0.009827:0.004551:0.009827:0.010357:0.004264:0.010326:0.005125:0.004264:0.014182:0.010326:0.007257:0.003024:0.014182:0.009192:0.014182:0.004264:0.009903:0.004551:0.004264:0.014182:0.010326:0.007257:0.003024:0.014182:0.010326:0.003024:0.003024:0.008104:0.004279:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.005125:0.009827:0.010357:0.004264:0.010357:0.009903:0.005866:0.009827:0.005866:0.004264:0.010326:0.009223:0.010357:0.004264:0.010326:0.005125:0.004188
the appropriate dosing frequency.:@0.076187:0.679362:0.329793:0.679362:0.329793:0.663579:0.076187:0.663579:0.005125:0.009223:0.009827:0.004188:0.010326:0.010311:0.010311:0.004551:0.009903:0.010311:0.004551:0.003024:0.010326:0.005125:0.009827:0.004188:0.010357:0.009903:0.005866:0.003024:0.009223:0.010175:0.004188:0.004747:0.004551:0.009827:0.010311:0.009192:0.009827:0.009223:0.009782:0.008104:0.004188
Implicit in this definition is that the BP is taken correctly :@0.090474:0.694128:0.485141:0.694128:0.485141:0.678346:0.090474:0.678346:0.003417:0.014182:0.010311:0.003024:0.003024:0.009782:0.003024:0.005125:0.004007:0.003024:0.009223:0.003991:0.005125:0.009223:0.003024:0.005866:0.003991:0.010357:0.009827:0.003681:0.003681:0.009223:0.003024:0.005125:0.003024:0.009903:0.009223:0.003976:0.003024:0.005866:0.003991:0.005125:0.009223:0.010326:0.005125:0.003991:0.005125:0.009223:0.009827:0.003991:0.008678:0.008950:0.003991:0.003024:0.005866:0.003991:0.005125:0.010326:0.007590:0.009827:0.009223:0.003991:0.009782:0.009903:0.004551:0.004551:0.009827:0.009782:0.005125:0.003024:0.008104:0.004188
as  errors  in  office  BP  measurement  are  common.  It  is :@0.076187:0.708895:0.485141:0.708895:0.485141:0.693112:0.076187:0.693112:0.010326:0.005866:0.004188:0.002737:0.009827:0.004551:0.004551:0.009903:0.004536:0.005866:0.004188:0.002737:0.003024:0.009223:0.004188:0.002721:0.009903:0.004747:0.003681:0.003681:0.009782:0.009827:0.004188:0.002721:0.008678:0.008950:0.004188:0.002721:0.014182:0.009827:0.010326:0.005866:0.009192:0.004551:0.009827:0.014182:0.009827:0.009223:0.005125:0.004188:0.002721:0.010326:0.004551:0.009827:0.004188:0.002721:0.009782:0.009903:0.014182:0.014182:0.009903:0.009223:0.004188:0.004188:0.002721:0.003417:0.005125:0.004188:0.002721:0.003024:0.005866:0.004188
essential that Bp is measured and recorded according :@0.076187:0.723662:0.485141:0.723662:0.485141:0.707879:0.076187:0.707879:0.009827:0.005866:0.005866:0.009827:0.009223:0.005125:0.003024:0.010326:0.003024:0.005156:0.005125:0.009223:0.010326:0.005125:0.005140:0.008678:0.008950:0.005140:0.003024:0.005866:0.005156:0.014182:0.009827:0.010326:0.005866:0.009192:0.004551:0.009827:0.010357:0.005140:0.010326:0.009223:0.010357:0.005156:0.004551:0.009827:0.009782:0.009903:0.004551:0.010357:0.009827:0.010357:0.005140:0.010326:0.009782:0.009782:0.009903:0.004551:0.010357:0.003024:0.009223:0.010175:0.004188
to south African hypertension guidelines in the appro-:@0.519038:0.168556:0.923790:0.168556:0.923790:0.152774:0.519038:0.152774:0.005125:0.009903:0.005912:0.007529:0.009903:0.009192:0.005125:0.009223:0.005896:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.009223:0.005896:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009207:0.005912:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.005912:0.003024:0.009223:0.005912:0.005125:0.009223:0.009827:0.005896:0.010326:0.010311:0.010311:0.004551:0.009903:0.005020
priate way, with a validated and calibrated Bp-meas-:@0.519038:0.182850:0.923790:0.182850:0.923790:0.167067:0.519038:0.167067:0.010311:0.004551:0.003024:0.010326:0.005125:0.009827:0.005851:0.012564:0.010326:0.008104:0.004188:0.005851:0.012564:0.003024:0.005125:0.009223:0.005851:0.010326:0.005851:0.008376:0.010326:0.003024:0.003024:0.010357:0.010326:0.005125:0.009827:0.010357:0.005866:0.010326:0.009223:0.010357:0.005851:0.009782:0.010326:0.003024:0.003024:0.010311:0.004551:0.010326:0.005125:0.009827:0.010357:0.005851:0.008678:0.008950:0.005020:0.014182:0.009827:0.010326:0.005866:0.005020
uring device. :@0.519038:0.197143:0.618960:0.197143:0.618960:0.181360:0.519038:0.181360:0.009192:0.004551:0.003024:0.009223:0.010175:0.004188:0.010357:0.009827:0.008376:0.003024:0.009782:0.009827:0.004188:0.004188
PAtients At risK:@0.519047:0.230199:0.665399:0.230199:0.665399:0.210034:0.519047:0.210034:0.010348:0.013674:0.007761:0.005174:0.009609:0.013674:0.007761:0.009609:0.005174:0.013674:0.007761:0.005174:0.010718:0.005174:0.009609:0.011457
Demographic correlates of RH include black race, old-:@0.519047:0.246272:0.923799:0.246272:0.923799:0.230489:0.519047:0.230489:0.011249:0.009827:0.014182:0.009903:0.010175:0.004551:0.010326:0.010311:0.009223:0.003024:0.009782:0.004687:0.009782:0.009903:0.004551:0.004551:0.009827:0.003024:0.010326:0.005125:0.009827:0.005866:0.004687:0.009903:0.004747:0.004687:0.009177:0.010326:0.004687:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.004687:0.010311:0.003024:0.010326:0.009782:0.007590:0.004702:0.004551:0.010326:0.009782:0.009827:0.004188:0.004687:0.009903:0.003024:0.010357:0.005020
er age, visceral obesity, CKD, diabetes mellitus, higher :@0.519047:0.260565:0.928002:0.260565:0.928002:0.244782:0.519047:0.244782:0.009827:0.004551:0.005700:0.010326:0.010175:0.009827:0.004188:0.005700:0.008376:0.003024:0.005866:0.009782:0.009827:0.004551:0.010326:0.003024:0.005715:0.009903:0.010311:0.009827:0.005866:0.003024:0.005125:0.008104:0.004188:0.005700:0.012292:0.008935:0.011249:0.004188:0.005700:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.005715:0.014182:0.009827:0.003024:0.003024:0.003024:0.005125:0.009192:0.005866:0.004188:0.005715:0.009223:0.003024:0.010175:0.009223:0.009827:0.004551:0.004188
Framingham 10-year risk and male sex.  patients with RH :@0.519047:0.274858:0.928001:0.274861:0.928001:0.259079:0.519047:0.259076:0.007333:0.004551:0.010326:0.014182:0.003024:0.009223:0.010175:0.009223:0.010326:0.014182:0.003795:0.008376:0.008376:0.005020:0.008104:0.009827:0.010326:0.004551:0.003810:0.004551:0.003024:0.005866:0.007590:0.003810:0.010326:0.009223:0.010357:0.003810:0.014182:0.010326:0.003024:0.009827:0.003810:0.005866:0.009827:0.007257:0.004188:0.004852:0.003810:0.008950:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003795:0.012564:0.003024:0.005125:0.009223:0.003810:0.009177:0.010326:0.046441
4:@0.800631:0.269563:0.805489:0.269563:0.805489:0.260409:0.800631:0.260409:0.004858
are also more likely to have non-dipping/reverse hyper-:@0.519046:0.289155:0.923798:0.289155:0.923798:0.273372:0.519046:0.273372:0.010326:0.004551:0.009827:0.004112:0.010326:0.003024:0.005866:0.009903:0.004127:0.014182:0.009903:0.004551:0.009827:0.004112:0.003024:0.003024:0.007590:0.009827:0.003024:0.008104:0.004127:0.005125:0.009903:0.004112:0.009223:0.010326:0.008376:0.009827:0.004127:0.009223:0.009903:0.009223:0.005020:0.010357:0.003024:0.010311:0.010311:0.003024:0.009223:0.010175:0.006607:0.004551:0.009827:0.008376:0.009827:0.004551:0.005866:0.009827:0.004112:0.009223:0.008104:0.010311:0.009827:0.004551:0.005020
tension, increased sympathetic nervous system over-:@0.519046:0.303448:0.923813:0.303448:0.923813:0.287665:0.519046:0.287665:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004188:0.008225:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.008225:0.005866:0.008104:0.014182:0.010311:0.010326:0.005125:0.009223:0.009827:0.005125:0.003024:0.009782:0.008225:0.009223:0.009827:0.004551:0.008376:0.009903:0.009192:0.005866:0.008225:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.008225:0.009903:0.008376:0.009827:0.004551:0.005020
activity, and  excess aldosterone.  Contrary  to  reports :@0.519046:0.317741:0.928016:0.317741:0.928016:0.301958:0.519046:0.301958:0.010326:0.009782:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.004188:0.008013:0.010326:0.009223:0.010357:0.004188:0.003810:0.009827:0.007257:0.009782:0.009827:0.005866:0.005866:0.008013:0.010326:0.003024:0.010357:0.009903:0.005866:0.005125:0.009827:0.004551:0.009903:0.009223:0.009827:0.004188:0.004188:0.003810:0.012292:0.009903:0.009223:0.005125:0.004551:0.010326:0.004551:0.008104:0.004188:0.003810:0.005125:0.009903:0.004188:0.003810:0.004551:0.009827:0.010311:0.009903:0.004551:0.005125:0.005866:0.004188
about a study in  south  Africa done  predominately in :@0.519046:0.332034:0.928001:0.332034:0.928001:0.316252:0.519046:0.316252:0.010326:0.010311:0.009903:0.009192:0.005125:0.006849:0.010326:0.006849:0.005866:0.005125:0.009192:0.010357:0.008104:0.006849:0.003024:0.009223:0.004188:0.002661:0.007529:0.009903:0.009192:0.005125:0.009223:0.004188:0.002646:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.006849:0.010357:0.009903:0.009223:0.009827:0.004188:0.002646:0.010311:0.004551:0.009827:0.010357:0.009903:0.014182:0.003024:0.009223:0.010326:0.005125:0.009827:0.003024:0.008104:0.006849:0.003024:0.009223:0.004188
black and mixed-ancestry patients, RH was found to be :@0.519046:0.346328:0.927986:0.346328:0.927986:0.330545:0.519046:0.330545:0.010311:0.003024:0.010326:0.009782:0.007590:0.003946:0.010326:0.009223:0.010357:0.003931:0.014182:0.003024:0.007257:0.009827:0.010357:0.005020:0.010326:0.009223:0.009782:0.009827:0.005866:0.005125:0.004551:0.008104:0.003931:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.003931:0.009177:0.010326:0.003931:0.012564:0.010326:0.005866:0.003946:0.004747:0.009903:0.009192:0.009223:0.010357:0.003931:0.005125:0.009903:0.003931:0.010311:0.009827:0.004188
more common in leaner subjects.  :@0.519046:0.360621:0.772709:0.360630:0.772709:0.344847:0.519046:0.344838:0.014182:0.009903:0.004551:0.009827:0.004188:0.009782:0.009903:0.014182:0.014182:0.009903:0.009223:0.004188:0.003024:0.009223:0.004188:0.003024:0.009827:0.010326:0.009223:0.009827:0.004551:0.004188:0.005866:0.009192:0.010311:0.003069:0.009827:0.009782:0.005125:0.005866:0.004188:0.004834:0.089417
5:@0.763661:0.355331:0.768519:0.355331:0.768519:0.346177:0.763661:0.346177:0.004858
PrACtiCAl APPrOACH:@0.519047:0.393672:0.723793:0.393672:0.723793:0.373507:0.519047:0.373507:0.010348:0.010718:0.013674:0.014413:0.007761:0.005174:0.014413:0.013674:0.008131:0.005174:0.013674:0.010348:0.010348:0.010718:0.015522:0.013674:0.014413:0.012566
A  practical guide to  the  approach  to  RH is outlined :@0.519047:0.409744:0.927972:0.409744:0.927972:0.393962:0.519047:0.393962:0.011188:0.004188:0.003326:0.010311:0.004551:0.010326:0.009782:0.005125:0.003024:0.009782:0.010326:0.003024:0.007529:0.010175:0.009192:0.003024:0.010357:0.009827:0.007529:0.005125:0.009903:0.004188:0.003326:0.005125:0.009223:0.009827:0.004188:0.003326:0.010326:0.010311:0.010311:0.004551:0.009903:0.010326:0.009782:0.009223:0.004188:0.003326:0.005125:0.009903:0.004188:0.003326:0.009177:0.010326:0.007529:0.003024:0.005866:0.007529:0.009903:0.009192:0.005125:0.003024:0.003024:0.009223:0.009827:0.010357:0.004188
in Figure 1, but for a detailed review of the topic the :@0.519047:0.424038:0.927987:0.424038:0.927987:0.408255:0.519047:0.408255:0.003024:0.009223:0.006410:0.007333:0.003024:0.010175:0.009192:0.004551:0.009812:0.006410:0.008376:0.004188:0.006410:0.010311:0.009192:0.005125:0.006410:0.004747:0.009903:0.004551:0.006410:0.010326:0.006410:0.010357:0.009827:0.005125:0.010326:0.003024:0.003024:0.009827:0.010357:0.006410:0.004551:0.009827:0.008376:0.003024:0.009827:0.012564:0.006410:0.009903:0.004747:0.006410:0.005125:0.009223:0.009827:0.006410:0.005125:0.009903:0.010311:0.003024:0.009782:0.006410:0.005125:0.009223:0.009827:0.004188
reader is referred to the following reference: :@0.519047:0.438331:0.858228:0.438331:0.858228:0.422548:0.519047:0.422548:0.004551:0.009827:0.010326:0.010357:0.009827:0.004551:0.006214:0.003024:0.005866:0.006229:0.004551:0.009827:0.004747:0.009827:0.004551:0.004536:0.009827:0.010357:0.006214:0.005125:0.009903:0.006214:0.005125:0.009223:0.009827:0.006214:0.004747:0.009903:0.003024:0.003024:0.009903:0.012564:0.003024:0.009223:0.010175:0.006214:0.004551:0.009827:0.004747:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.004188:0.004188
Resistant :@0.860254:0.438331:0.928002:0.438331:0.928002:0.422548:0.860254:0.422548:0.009177:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.005125:0.004188
Hypertension: Detection, Evaluation and Management: :@0.519047:0.452624:0.928002:0.452624:0.928002:0.436842:0.519047:0.436842:0.010326:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004188:0.003780:0.011249:0.009827:0.005125:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.003780:0.008104:0.008376:0.010326:0.003024:0.009192:0.010326:0.005125:0.003024:0.009903:0.009223:0.003795:0.010326:0.009223:0.010357:0.003795:0.013894:0.010326:0.009223:0.010326:0.010175:0.009827:0.014182:0.009827:0.009223:0.005125:0.004188:0.004188
A Scientific Statement from the American Heart Asso:@0.519047:0.466918:0.918810:0.466918:0.918810:0.451135:0.519047:0.451135:0.011188:0.006426:0.007529:0.009782:0.003024:0.009827:0.009223:0.005125:0.003024:0.003681:0.003681:0.009782:0.006426:0.007529:0.005125:0.010326:0.005125:0.009827:0.014182:0.009827:0.009223:0.005125:0.006410:0.004747:0.004551:0.009903:0.014182:0.006426:0.005125:0.009223:0.009827:0.006426:0.011188:0.014182:0.009827:0.004551:0.003024:0.009782:0.010326:0.009223:0.006426:0.010326:0.009827:0.010326:0.004551:0.005125:0.006426:0.011188:0.005866:0.005866:0.009903
-:@0.918810:0.466918:0.923829:0.466918:0.923829:0.451135:0.918810:0.451135:0.005020
ciation.  :@0.519047:0.481211:0.582688:0.481218:0.582688:0.465436:0.519047:0.465428:0.009782:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.004857:0.121525
4:@0.573640:0.475920:0.578498:0.475920:0.578498:0.466766:0.573640:0.466766:0.004858
Once apparent treatment resistance has been :@0.582173:0.481218:0.928021:0.481218:0.928021:0.465436:0.582173:0.465436:0.013138:0.009223:0.009782:0.009827:0.003674:0.010326:0.010311:0.010311:0.010326:0.004551:0.009827:0.009223:0.005125:0.003674:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.003659:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.003674:0.009223:0.010326:0.005866:0.003674:0.010311:0.009827:0.009827:0.009223:0.004188
excluded, referral to a specialist is recommended.:@0.519051:0.495512:0.886021:0.495512:0.886021:0.479729:0.519051:0.479729:0.009827:0.007257:0.009782:0.003024:0.009192:0.010357:0.009827:0.010357:0.004188:0.004188:0.004551:0.009827:0.004747:0.009827:0.004551:0.004551:0.010326:0.003024:0.004188:0.005125:0.009903:0.004188:0.010326:0.004188:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.005866:0.005125:0.004188:0.003024:0.005866:0.004188:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188
exClusiOn Of APPArent  :@0.519047:0.528555:0.754431:0.528555:0.754431:0.508390:0.519047:0.508390:0.009609:0.012566:0.014413:0.008131:0.011826:0.009609:0.005174:0.015522:0.013674:0.005174:0.015522:0.008870:0.005174:0.013674:0.010348:0.010348:0.013674:0.010718:0.009609:0.013674:0.007761:0.005137:0.005174
treAtment resistAnCe:@0.519047:0.545418:0.725271:0.545418:0.725271:0.525253:0.519047:0.525253:0.007761:0.010718:0.009609:0.013674:0.007761:0.016631:0.009609:0.013674:0.007761:0.005174:0.010718:0.009609:0.009609:0.005174:0.009609:0.007761:0.013674:0.013674:0.014413:0.009609
The four most important causes of apparent treatment :@0.519047:0.561488:0.928002:0.561488:0.928002:0.545705:0.519047:0.545705:0.006441:0.009223:0.009827:0.005035:0.004747:0.009903:0.009192:0.004551:0.005020:0.014182:0.009903:0.005866:0.005125:0.005035:0.003024:0.014182:0.010311:0.009903:0.004551:0.005125:0.010326:0.009223:0.005125:0.005020:0.009782:0.010326:0.009192:0.005866:0.009827:0.005866:0.005035:0.009903:0.004747:0.005035:0.010326:0.010311:0.010311:0.010326:0.004551:0.009827:0.009223:0.005125:0.005035:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188
resistance are  incorrect  Bp measurement  (discussed :@0.519047:0.575781:0.927987:0.575781:0.927987:0.559999:0.519047:0.559999:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.009087:0.010326:0.004551:0.009827:0.004188:0.004883:0.003024:0.009223:0.009782:0.009903:0.004551:0.004551:0.009827:0.009782:0.005125:0.004188:0.004883:0.008678:0.008950:0.009087:0.014182:0.009827:0.010326:0.005866:0.009192:0.004551:0.009827:0.014182:0.009827:0.009223:0.005125:0.004188:0.004883:0.005579:0.010357:0.003024:0.005866:0.009782:0.009192:0.005866:0.005866:0.009827:0.010357:0.004188
above), treatment  inertia,  non-adherence  and super-:@0.519047:0.590075:0.923799:0.590075:0.923799:0.574292:0.519047:0.574292:0.010326:0.010311:0.009903:0.008376:0.009827:0.005579:0.004188:0.006547:0.005125:0.004551:0.009827:0.010326:0.005125:0.014167:0.009827:0.009223:0.005125:0.004188:0.002343:0.003024:0.009223:0.009827:0.004551:0.005125:0.003024:0.010326:0.004188:0.004188:0.002343:0.009223:0.009903:0.009223:0.005020:0.010326:0.010357:0.009223:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.004188:0.002328:0.010326:0.009223:0.010357:0.006547:0.005866:0.009192:0.010311:0.009827:0.004551:0.005020
added white-coat effect.:@0.519047:0.604368:0.706811:0.604368:0.706811:0.588585:0.519047:0.588585:0.010326:0.010357:0.010357:0.009827:0.010357:0.004188:0.012564:0.009223:0.003024:0.005125:0.009827:0.005020:0.009782:0.009903:0.010326:0.005125:0.004188:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004188
non-adherence:@0.519047:0.635738:0.650079:0.635738:0.650079:0.617406:0.519047:0.617406:0.012431:0.010751:0.010079:0.007056:0.011087:0.011087:0.010079:0.010751:0.005376:0.010751:0.010079:0.010751:0.010751
Non-adherence  is  a major issue  in achieving Bp con-:@0.519047:0.652204:0.923814:0.652204:0.923814:0.636422:0.519047:0.636422:0.011188:0.009903:0.009223:0.005020:0.010326:0.010357:0.009223:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.004188:0.002631:0.003024:0.005866:0.004188:0.002661:0.010326:0.006834:0.014182:0.010326:0.003069:0.009903:0.004551:0.006834:0.003024:0.005866:0.005866:0.009192:0.009827:0.004188:0.002661:0.003024:0.009223:0.006834:0.010326:0.009782:0.009223:0.003024:0.009827:0.008376:0.003024:0.009223:0.010175:0.006834:0.008678:0.008950:0.006834:0.009782:0.009903:0.009223:0.005020
trol.  In newly diagnosed hypertensives, up to 50% are :@0.519047:0.666498:0.927987:0.666498:0.927987:0.650715:0.519047:0.650715:0.005125:0.004551:0.009903:0.003024:0.004188:0.004188:0.002359:0.003417:0.009223:0.006562:0.009223:0.009827:0.012564:0.003024:0.008104:0.006562:0.010357:0.003024:0.010326:0.010175:0.009223:0.009903:0.005866:0.009827:0.010357:0.006562:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.005866:0.004188:0.006562:0.009192:0.010311:0.006562:0.005125:0.009903:0.006562:0.008376:0.008376:0.011717:0.006562:0.010326:0.004551:0.009827:0.004188
non-adherent in the  first  year.:@0.519047:0.680791:0.743006:0.680791:0.743006:0.665008:0.519047:0.665008:0.009223:0.009903:0.009223:0.005020:0.010326:0.010357:0.009223:0.009827:0.004551:0.009827:0.009223:0.005125:0.006441:0.003024:0.009223:0.006456:0.005125:0.009223:0.009827:0.004188:0.002268:0.003681:0.003681:0.004551:0.005866:0.005125:0.004188:0.002268:0.008104:0.009827:0.010326:0.004551:0.004188
6:@0.743014:0.675495:0.747872:0.675495:0.747872:0.666341:0.743014:0.666341:0.004858
  Factors  contributing  to :@0.747874:0.680794:0.928002:0.680794:0.928002:0.665011:0.747874:0.665011:0.004188:0.002268:0.007333:0.010326:0.009782:0.005125:0.009903:0.004551:0.005866:0.004188:0.002268:0.009782:0.009903:0.009223:0.005125:0.004551:0.003024:0.010311:0.009192:0.005125:0.003024:0.009223:0.010175:0.004188:0.002268:0.005125:0.009903:0.004188
poor adherence are myriad and multilevel, and the ap-:@0.519047:0.695087:0.923799:0.695087:0.923799:0.679304:0.519047:0.679304:0.010311:0.009903:0.009903:0.004551:0.003674:0.010326:0.010357:0.009223:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.003674:0.010326:0.004551:0.009827:0.003674:0.014182:0.008104:0.004551:0.003024:0.010326:0.010357:0.003689:0.010326:0.009223:0.010357:0.003689:0.014182:0.009192:0.003024:0.005125:0.003024:0.003024:0.009827:0.008376:0.009827:0.003024:0.004188:0.003689:0.010326:0.009223:0.010357:0.003674:0.005125:0.009223:0.009827:0.003674:0.010326:0.010311:0.005020
proach  is multifaceted and beyond the  scope of  this :@0.519047:0.709380:0.927987:0.709380:0.927987:0.693598:0.519047:0.693598:0.010311:0.004551:0.009903:0.010326:0.009782:0.009223:0.004188:0.002283:0.003024:0.005866:0.006486:0.014182:0.009192:0.003024:0.005125:0.003024:0.004747:0.010326:0.009782:0.009827:0.005125:0.009827:0.010357:0.006486:0.010326:0.009223:0.010357:0.006486:0.010311:0.009827:0.008104:0.009903:0.009223:0.010357:0.006486:0.005125:0.009223:0.009827:0.004188:0.002283:0.005866:0.009782:0.009903:0.010311:0.009827:0.006486:0.009903:0.004747:0.004188:0.002283:0.005125:0.009223:0.003024:0.005866:0.004188
short article. However, the detection of non-adherence :@0.519047:0.723673:0.928032:0.723673:0.928032:0.707891:0.519047:0.707891:0.005866:0.009223:0.009903:0.004551:0.005125:0.003886:0.010326:0.004551:0.005125:0.003024:0.009782:0.003024:0.009827:0.004188:0.003901:0.010326:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.003901:0.005125:0.009223:0.009827:0.003901:0.010357:0.009827:0.005125:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.003901:0.009903:0.004747:0.003901:0.009223:0.009903:0.009223:0.005020:0.010326:0.010357:0.009223:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.004188
figure 1. Approach to the patient with resistant hypertension:@0.076195:0.944064:0.514043:0.944064:0.514043:0.927566:0.076195:0.927566:0.007257:0.003629:0.009979:0.009071:0.004838:0.009676:0.004233:0.008467:0.004233:0.004233:0.011188:0.009979:0.009979:0.004838:0.009676:0.009979:0.009676:0.009071:0.004233:0.004536:0.009676:0.004233:0.004536:0.009071:0.009676:0.004233:0.009979:0.009979:0.004536:0.003629:0.009676:0.009071:0.004536:0.004233:0.012095:0.003629:0.004536:0.009071:0.004233:0.004838:0.009676:0.006652:0.003629:0.006652:0.004536:0.009979:0.009071:0.004536:0.004233:0.009071:0.008769:0.009979:0.009676:0.004838:0.004536:0.009676:0.009071:0.006652:0.003629:0.009676:0.009071
Evaluation of patient:@0.209231:0.759053:0.344885:0.759053:0.344885:0.745024:0.209231:0.745024:0.007203:0.007445:0.009179:0.002688:0.008171:0.009179:0.004556:0.002688:0.008803:0.008198:0.003723:0.008803:0.004220:0.003723:0.009165:0.009179:0.004556:0.002688:0.008735:0.008198:0.004556
Appropriate treatment:@0.197555:0.793211:0.345937:0.793211:0.345937:0.779182:0.197555:0.779182:0.009945:0.009165:0.009165:0.004045:0.008803:0.009165:0.004045:0.002688:0.009179:0.004556:0.008735:0.003723:0.004556:0.004045:0.008735:0.009179:0.004556:0.012606:0.008735:0.008198:0.004556
Bp not at goal:@0.407206:0.794490:0.499049:0.794490:0.499049:0.780461:0.407206:0.780461:0.007714:0.007956:0.003723:0.008198:0.008803:0.004556:0.003723:0.009179:0.004556:0.003723:0.009045:0.008803:0.009179:0.002688
Bp at goal +/- 85%:@0.116039:0.845837:0.233834:0.845837:0.233834:0.831808:0.116039:0.831808:0.007714:0.007956:0.003723:0.009179:0.004556:0.003723:0.009045:0.008803:0.009179:0.002688:0.003723:0.008144:0.005873:0.004462:0.003723:0.007445:0.007445:0.010415
patient, funder :@0.485992:0.828339:0.585589:0.828339:0.585589:0.814310:0.485992:0.814310:0.007956:0.009179:0.004556:0.002688:0.008735:0.008198:0.004556:0.003723:0.003723:0.004220:0.008171:0.008198:0.009206:0.008735:0.004032:0.003723
or physician:@0.485992:0.841167:0.563791:0.841167:0.563791:0.827138:0.485992:0.827138:0.008803:0.004045:0.003723:0.009165:0.008198:0.007203:0.005214:0.002688:0.008695:0.002688:0.009179:0.008198
failure:@0.485992:0.853995:0.525718:0.853995:0.525718:0.839966:0.485992:0.839966:0.004220:0.009179:0.002688:0.002688:0.008171:0.004045:0.008735
secondary causes:@0.485203:0.883757:0.604892:0.883757:0.604892:0.869728:0.485203:0.869728:0.006693:0.008735:0.008695:0.008803:0.008198:0.009206:0.009179:0.004045:0.007203:0.003723:0.008695:0.009179:0.008171:0.005214:0.008735:0.005214
true resistance 2%:@0.390452:0.917781:0.509792:0.917781:0.509792:0.903116:0.390452:0.903116:0.005644:0.004301:0.008063:0.008601:0.003763:0.004301:0.008601:0.005913:0.003225:0.005913:0.004032:0.008870:0.008063:0.008601:0.008601:0.003763:0.007526:0.011558
superadded white coating:@0.703793:0.751805:0.880088:0.751805:0.880088:0.737776:0.703793:0.737776:0.006693:0.008171:0.009165:0.008735:0.004045:0.009179:0.009206:0.009206:0.008735:0.009206:0.003723:0.011168:0.008198:0.002688:0.004556:0.008735:0.003723:0.008695:0.008803:0.009179:0.004556:0.002688:0.008198:0.009045
physician inertia:@0.726625:0.779654:0.830456:0.779654:0.830456:0.765625:0.726625:0.765625:0.007956:0.008198:0.007203:0.005214:0.002688:0.008695:0.002688:0.009179:0.008198:0.003723:0.002688:0.008198:0.008735:0.004045:0.004556:0.002688:0.009179
Non-adherence:@0.740777:0.806582:0.845912:0.806582:0.845912:0.792553:0.740777:0.792553:0.009945:0.008803:0.008198:0.004462:0.009179:0.009206:0.008198:0.008735:0.004045:0.008735:0.008198:0.008695:0.008735
Lack of lifestyle changes:@0.741617:0.834419:0.900629:0.834419:0.900629:0.820390:0.741617:0.820390:0.006209:0.009179:0.008695:0.006746:0.003723:0.008803:0.004220:0.003723:0.002688:0.002688:0.004220:0.008735:0.005214:0.004556:0.007203:0.002688:0.008735:0.003723:0.008695:0.008198:0.009179:0.008198:0.009045:0.008735:0.005214
Interfering drugs:@0.744444:0.861615:0.849350:0.861615:0.849350:0.847586:0.744444:0.847586:0.003037:0.008198:0.004556:0.008735:0.004045:0.004220:0.008735:0.004045:0.002688:0.008198:0.009045:0.003723:0.009206:0.004045:0.008171:0.009045:0.005214
Inappropriate formularies:@0.737809:0.890344:0.901888:0.890344:0.901888:0.876315:0.737809:0.876315:0.003037:0.008198:0.009179:0.009165:0.009165:0.004045:0.008803:0.009165:0.004045:0.002688:0.009179:0.004556:0.008735:0.003723:0.004220:0.008803:0.004045:0.012606:0.008171:0.002688:0.009179:0.004045:0.002688:0.008735:0.005214
No single-pill combinations:@0.722817:0.917931:0.896061:0.917931:0.896061:0.903902:0.722817:0.903902:0.009945:0.008803:0.003723:0.005214:0.002688:0.008198:0.009045:0.002688:0.008735:0.004462:0.009165:0.002688:0.002688:0.002688:0.003723:0.008695:0.008803:0.012606:0.009165:0.002688:0.008198:0.009179:0.004556:0.002688:0.008803:0.008198:0.005214